INTRODUCTION {#s1}
============

Pancreatic stellate cells (PaSCs) are non-endocrine, mesenchymal-like cells \[[@R1]-[@R3]\] that reside in the peri-acinar, peri-ductal and peri-vascular area and play a role in regulating extracellular matrix (ECM) turnover, which is important for maintaining the integrity of pancreatic tissues architecture \[[@R4]\]. In the adult human pancreas, there is emerging evidence that interplay between PaSCs and the surrounding ECM is required for pancreatic tissue repair and involved in pathophysiological processes including inflammation and pancreatic fibrosis \[[@R5]\]. However, little is known about the interaction between PaSCs integrin receptors and various ECM components in the developing human pancreas.

Integrins are cell adhesion receptors that play an integral role in cell-cell and cell-ECM communication in many cell types, including rodent PaSCs. Among integrin receptors, β1 integrin associates with 12 α subunits \[[@R6]\] and mediates cellular binding to multiple extracellular matrix proteins (i.e., collagens, laminin, fibronectin) \[[@R7]\]. Stimulation of β1 integrin down-stream signaling pathways are important for cell migration, differentiation, proliferation, and survival \[[@R7]-[@R9]\]. Our recent study elucidated the functional role of β1 integrin in PaSCs using an inducible β1 integrin knockout mouse model \[[@R10]\]. We found that β1 integrin deficiency in collagen I-producing PaSCs impaired basement membrane integrity and function with loss of ECM expression in the pancreas, which in turn affected acinar cell proliferation and function \[[@R10]\]. The connective tissue growth factor (CTGF), a known activator of PaSCs, requires α5β1 integrin to promote rat PaSCs adhesion, migration, proliferation, and cytokine secretion \[[@R11]\]. In the developing human pancreas, the α3β1 integrin is highly expressed in fetal islet cells and co-localizes with collagen IV \[[@R12]\]. Interactions between α3β1 and collagen I or IV activate both the MAPK/ERK and the PI3K/AKT signaling pathways, suggesting that they are critical for modulating islet cell differentiation, proliferation, and survival in the developing human pancreas \[[@R13]\]. Despite these previous studies, the functional role of β1 integrin directly affecting PaSCs in the developing human pancreas has yet to be examined.

In this study, PaSCs were isolated from human fetal pancreata collected during the 2^nd^ trimester of pregnancy and characterized as follows: the expression pattern of β1 integrin associated with α subunits in human PaSCs were examined, and cell behaviors such as adhesion, migration, proliferation, and function were studied following exposure to various matrix proteins. Our results revealed that the collagen I matrix increased α3β1 integrin-dependent PaSC adhesion and migration, enhanced PaSC proliferation, and increased TGFβ1 and CTGF production via activation of the FAK/ERK and AKT signaling pathways. Similar results were obtained when using a β1 integrin blockade study. This study demonstrated that β1 integrin association with α3 integrin is required for the proliferation and proper function of human fetal PaSCs on a collagen I matrix, and provide a better understanding of PaSC-ECM interactions in the developing human pancreas.

RESULTS {#s2}
=======

Characterization of purified human fetal PaSCs {#s2_1}
----------------------------------------------

Using a modified outgrowth method \[[@R14]\], human fetal PaSCs were outgrown to form monolayers within 3 weeks of the culture, where the phase-contrast (PH) micrograph of quiescent PaSCs for lipid droplet content was used to confirm PaSC phenotype (Figure [1A](#F1){ref-type="fig"}). The purity of PaSCs was assessed by immunofluorescence staining and western blot analysis, and showed positive labeling for stellate cell selective markers (desmin, vimentin, GFAP, and αSMA), but not for cytokeratin 19 (a ductal cell marker) and stromal cell surface marker (Figure [1B](#F1){ref-type="fig"}). The matrix proteins, collagen I and IV, laminin, and fibronectin, were also expressed in isolated human PaSCs (Figure [1B](#F1){ref-type="fig"}). Western blot analyses further verified PaSCs markers (Figure [1C](#F1){ref-type="fig"}), and growth factors (TGFβ1 and CTGF) in cultured human PaSCs from 2 to 5 passages (Figure [1D](#F1){ref-type="fig"}). This data indicates that purified PaSCs isolated from human fetal pancreata could be used for the following experiments.

![Characterization of isolated human fetal PaSCs\
**A.** Phase-contrast micrographs of quiescent human fetal PaSCs. Scale bar: 50μm. Arrows indicate lipid droplets in PaSCs. **B.** Representative images of immunofluorescence staining for PaSC markers: desmin, vimentin, GFAP, and αSMA, along with ECM proteins: collagen I and IV, laminin, and fibronectin (green). Both CK19 (ductal cell marker) and stromal cell surface marker were not expressed in the human fetal PaSCs. Nuclei were stained with DAPI (blue). Scale bar: 50μm. Magnified images for desmin and vimentin are shown in the insets. Western blot analyses of PaSC markers **C.** and growth factors (TGFβ1 and CTGF) **D.** from cultured human fetal PaSCs, between passages 2 to 5 (*n* = 5-6 experiments/group). Representative blots are shown.](oncotarget-06-14045-g001){#F1}

Integrin expression in human fetal PaSCs {#s2_2}
----------------------------------------

β1 and β3 integrins and their associated α subunits, including α1-3, α5-6, and αv, were examined in isolated human PaSCs. Immunofluorescence staining of PaSCs showed the expression of α1-3, α5-6 and αv subunits along with β1 integrin, with relatively lower expression of β3 (Figure [2A](#F2){ref-type="fig"}). The staining data was corroborated with western blot analysis that showed higher levels of β1 integrin with α3 and α5 subunits (Figure [2B](#F2){ref-type="fig"}). These data suggest that α3β1 and α5β1 may play an integral role in the function and proliferation of human fetal PaSCs.

![Integrin expression in human fetal PaSCs\
**A.** Representative images of immunofluorescence staining for α1-3, α5-6, αv, β1 and β3 integrin (green) in cultured human fetal PaSCs. Nuclei were stained with DAPI (blue). Scale bar: 50μm. **B.** Western blot of α and β1 integrin expression in cultured human fetal PaSCs. Data are expressed as means ± SEM (*n* = 5-6 experiments/group). Representative blots are shown.](oncotarget-06-14045-g002){#F2}

Collagen I, IV, and fibronectin matrix proteins enhance PaSC adhesion and migration {#s2_3}
-----------------------------------------------------------------------------------

The common ligands for α3β1 integrin are fibronectin, laminin, collagen I, and collagen IV \[[@R15], [@R16]\], while fibronectin is the ligand for α5β1 integrin \[[@R17]-[@R19]\]. The adhesion of PaSCs to these common matrix components was examined individually. PaSCs showed strong adhesion to collagen I, collagen IV, and fibronectin within 20 minutes (Figure [3A](#F3){ref-type="fig"}), and the number of adherent cells increased by at least 3-fold with these matrix components compared to control (*p* \< 0.05-0.01, Figure [3B](#F3){ref-type="fig"}). PaSCs plated on laminin showed relatively lower adhesion when compared to PaSCs on collagen I (*p* \< 0.05, Figure [3B](#F3){ref-type="fig"}), with no significant difference compared to control (Figure [3B](#F3){ref-type="fig"}). To examine PaSC migration on these matrices, near confluent cell monolayers were wounded to form a gap and migration distance over the gap of PaSCs was measured after 24 hours. It was found that PaSC migration was enhanced on both collagens I and IV, and the gaps were closed completely within 24 hours (Figure [3C](#F3){ref-type="fig"}). However, gaps remained open on fibronectin, laminin, and control groups (Figure [3C](#F3){ref-type="fig"}), suggesting that human fetal PaSC migration is favored when cultured on collagen matrices.

![Collagen I, collagen IV, and fibronectin enhance PaSC adhesion and migration\
**A.** Phase-contrast micrographs of human fetal PaSCs plated on collagen I (Col I), IV (Col IV), fibronectin (FN), laminin (L) or BSA coated control (Ctrl) for 20 mins. **B.** The cell adhesion rate on various ECM matrices after 20 minutes. Data are expressed as means ± SEM (*n* = 4 experiments/group). *\*p \< 0.05*, *\*\*p \< 0.01* vs. control, and analyzed by one-way ANOVA followed by Tukey\'s post-hoc analyses. **C.** Phase-contrast micrographs of human fetal PaSC migration from wounded gaps at 0 and 24 hours on various ECM matrices. Scale bar: 100μm. Representative images are shown.](oncotarget-06-14045-g003){#F3}

Evaluation of the effect of collagen I on PaSC proliferation {#s2_4}
------------------------------------------------------------

Given that PaSCs cultured on collagen I demonstrated increased PaSC adhesion and migration, the proliferation, growth factors productions (i.e., TGFβl and CTGF) and associated signaling pathways were examined. The proliferative capacity of PaSCs was analyzed by immunofluorescence staining for nuclear Ki67 labeling (Figure [4A](#F4){ref-type="fig"}), and showed a significantly increased percentage of Ki67^+^ PaSCs when compared to control (*p* \< 0.05, Figure [4A](#F4){ref-type="fig"}). Both TGFβ1 and CTGF are key growth factors produced by PaSCs that stimulate the synthesis and secretion of ECM proteins (collagen, fibronectin, and laminin) \[[@R20], [@R21]\], and were significantly increased (TGFβ1, *p* \< 0.01, Figure [4B](#F4){ref-type="fig"}; CTGF, *p* \< 0.05, Figure [4C](#F4){ref-type="fig"}) in PaSCs when compared to the control group.

![Collagen I increases PaSC proliferation and growth factor production\
**A.** Representative images of immunofluorescence staining and quantitative analysis of Ki67^+^ (red) for PaSCs cultured on a control plate with BSA or collagen I matrix for 24 hours. Nuclei were stained with DAPI (blue). Scale bar: 25μm. Western blot analyses of TGFβ1 **B.** and CTGF **C.** protein levels in PaSCs cultured on control plate with BSA or collagen I matrix after 24 hours. Representative blots are shown. Data are expressed as means ± SEM (*n* = 4-5 experiments/group). *\*p \< 0.05, \*\*p \< 0.01 vs*. control, and analyzed by paired Student\'s *t*-test.](oncotarget-06-14045-g004){#F4}

Collagen I is a major activator of α3β1 integrin, and therefore was further examined to determine if PaSCs cultured on collagen I could enhance α3 and β1 integrin expression and stimulate its downstream signaling molecules involved in PaSC proliferation and function. It was noted that both β1 (*p* \< 0.01, Figure [5A](#F5){ref-type="fig"}) and α3 (*p* \< 0.05, Figure [5B](#F5){ref-type="fig"}) protein levels were significantly increased when PaSCs were cultured on collagen I, along with elevated phospho-FAK (*p* \< 0.05, Figure [5C](#F5){ref-type="fig"}) compared to the control group. Increasing activation of α3β1/FAK resulted in a significant increase of phospho-ERK1/2 (*p* \< 0.01, Figure [5D](#F5){ref-type="fig"}) and phospho-AKT (*p* \< 0.01, Figure [5E](#F5){ref-type="fig"}), along with an increase of cyclin D1 (*p* \< 0.01, Figure [5F](#F5){ref-type="fig"}) protein expression, in PaSCs. This data indicates that interaction of α3β1 integrin with collagen I could lead to activation of downstream FAK/ERK and AKT, along with cyclin D1 signaling pathways, resulting in increased PaSC proliferation and function.

![Collagen I enhances PaSC α3β1 integrin expression and downstream FAK/ERK, AKT, and cyclin D1 signaling\
Western blot analyses of β1 **A.** and α3 **B.** integrins, phosphorylated \[P\] and total \[T\] FAK **C.**, ERK **D.**, AKT **E.**, and cyclin D1 **F.** protein levels of PaSCs cultured on a control plate with BSA or collagen I matrix after 24 hours. Data are expressed as means ± SEM (*n* = 4-5 experiments/group). Representative blots are shown. *\*p \< 0.05*, *\*\*p \< 0.01 vs*. control, and analyzed by paired Student\'s *t*-test.](oncotarget-06-14045-g005){#F5}

Blocking β1 integrin reduces collagen I stimulated PaSC function and proliferation {#s2_5}
----------------------------------------------------------------------------------

To determine how β1 integrin is involved in regulating the adhesion and migration of PaSCs via the binding of collagen I, human fetal PaSCs were pretreated with human β1 immunoneutralizing antibody, IgG, or left untreated and plated on a collagen I matrix. PaSCs treated with anti-β1 integrin displayed a 50% reduction in cell adhesion to collagen I when compared with IgG and control groups, respectively (*p* \< 0.01-0.001, Figure [6A](#F6){ref-type="fig"}). Functional blockade of β1 integrin on PaSCs severely hampered their ability to migrate and cover the gaps on collagen I matrix (Figure [6B](#F6){ref-type="fig"}). No apparent difference in PaSC adhesion and migration was observed between IgG and control groups (Figure [6A](#F6){ref-type="fig"} and [6B](#F6){ref-type="fig"}). A significant decrease of Ki67^+^ labeling in PaSCs cultured on a collagen I matrix was observed following anti-β1 integrin treatment when compared to controls (*p \<* 0.01, Figure [7A](#F7){ref-type="fig"}). Furthermore, blocking β1 integrin on PaSCs showed relatively reduced TGFβ1 (*p \<* 0.05, Figure [7B](#F7){ref-type="fig"}) and CTGF (*p \<* 0.05-0.01, Figure [7C](#F7){ref-type="fig"}) protein levels when compared to the controls. This β1 integrin blocking study indicates that β1 integrin interactions with the collagen I are essential for maintaining human fetal PaSC adhesion, migration, proliferation, and production of certain growth factors.

![β1 integrin blockade reduces PaSC adhesion and migration on collagen I\
**A.** Phase-contrast micrograph of human fetal PaSC adhesion and quantitative analyses of PaSC adhesion rate in anti-β1 integrin, IgG, and control experimental groups cultured on a collagen I matrix after 20 minutes. Data are expressed as means ± SEM (*n* = 3 experiments/group). \**p* \< 0.05, \*\**p* \< 0.01 *vs*. control, and analyzed by one-way ANOVA followed by Tukey\'s post-hoc analyses. **B.** Phase-contrast micrographs of human fetal PaSC migration from wounded gaps at 0 and 24 hours on collagen I matrix. Scale bar: 100μm. Representative images are shown.](oncotarget-06-14045-g006){#F6}

![β1 integrin blockade decreases PaSC proliferation and associated growth factor levels\
**A.** Representative images of immunofluorescence staining and quantitative analyses of Ki67^+^ (red) PaSCs in anti-β1 integrin, IgG and control experimental groups cultured on a collagen I matrix for 24 hours. Nuclei were stained with DAPI (blue). Scale bar: 25μm. Western blot analysis of PaSC TGFβ1 **B.** or CTGF **C.** protein levels in anti-β1 integrin, IgG, and control experimental groups cultured on collagen I for 24 hours. Representative blots are shown. Data are expressed as means ± SEM (*n* = 3-5 experiments/group). *\*p \< 0.05 and \*\*p \< 0.01 vs* control group, and data were analyzed by one-way ANOVA followed by Tukey\'s and Fisher\'s least significant difference post-hoc analyses.](oncotarget-06-14045-g007){#F7}

Perturbing β1 integrin function decreases FAK and ERK1/2, but not AKT activation in PaSCs cultured on a collagen I matrix {#s2_6}
-------------------------------------------------------------------------------------------------------------------------

Since collagen I promoted PaSC proliferation and production of TGFβ1 and CTGF via the α3 and β1 integrin-stimulated MAPK and PI3K pathways, we examined whether blocking β1 integrin impeded PaSC function and survival via the same pathways. Blocking β1 integrin on PaSCs cultured on a collagen I matrix did not affect the protein levels of β1 (Figure [8A](#F8){ref-type="fig"}) and α3 (Figure [8B](#F8){ref-type="fig"}) integrin. However, a significant reduction in the phosphorylation of FAK (*p* \< 0.05, Figure [8C](#F8){ref-type="fig"}) and phospho-ERK (*p* \< 0.05-0.01, Figure [8D](#F8){ref-type="fig"}), but not AKT (Figure [8E](#F8){ref-type="fig"}), signaling pathways was observed in the anti-β1 PaSC group. This data corroborates with our previous study using human fetal islet-epithelial cells \[[@R13]\]. Additionally, down-regulation of FAK/ERK signaling pathways in PaSCs induced by β1 integrin blockade led to reduced cyclin D1 expression (*p* \< 0.05-0.01, Figure [8F](#F8){ref-type="fig"}). This data further indicates that β1 integrin-collagen I interactions are critical for modulating PaSC proliferation and function through specialized signaling cascades.

![β1 integrin blockade decreases FAK, ERK1/2 and cyclin D1 signaling in PaSCs\
Western blot analyses of β1 **A.** and α3 **B.** integrins, phosphorylated \[P\] and total \[T\] FAK **C.**, ERK **D.**, AKT **E.**, and cyclinD1 **F.** protein levels of PaSCs cultured on collagen I in anti-β1 integrin, IgG, and control experimental groups. Data are expressed as means ± SEM (*n* = 3-5 experiments/groups). Representative blots are shown. *\*p \< 0.05 and \*\*p \< 0.01* vs control group, and analyzed by one-way ANOVA followed by Tukey\'s post-hoc analyses.](oncotarget-06-14045-g008){#F8}

DISCUSSION {#s3}
==========

In the present study, we have isolated and purified human PaSCs from developing pancreata and have demonstrated that β1 integrin and its associated α3 subunit is highly expressed in human fetal PaSCs. The activation of α3β1 integrin by collagen I matrix protein plays an important role in mediating human fetal PaSC adhesion, migration, proliferation, and growth factor production. Culturing human fetal PaSCs on collagen I not only enhanced α3β1 integrin expression, but also altered the integrin/FAK and downstream ERK and AKT signaling pathways, along with elevating cyclin D1 protein levels. Blocking β1 integrin on PaSCs resulted in significant down regulation of the FAK/ERK/cyclin D1 signaling pathways with no effect on the AKT pathway. This study provides the first *ex vivo* delineation of the mechanisms by which interaction of β1 integrin with collagen I protein regulates human fetal PaSC function and growth.

Using a modified PaSC isolation and purification protocol \[[@R14], [@R22]\], we showed that the stellate-like cells derived from the isolated human fetal pancreas expressed specific stellate markers including desmin, vimentin, GFAP, and αSMA, paired with the absence of CK19 and stromal cell markers, suggesting that ductal cells and mesenchymal stromal cells were not present as contaminants in isolated human PaSC populations \[[@R23]-[@R25]\]. More importantly, our purified human PaSCs retained functionality to produce various ECM and growth factors for at least 10 population doublings. Given this efficient method in isolating human fetal PaSCs, this study provided a sufficient cell number to elucidate PaSC function and PaSC-induced pancreatic diseases \[[@R26], [@R27]\], and also offers a novel opportunity to study PaSCs in pancreatic morphogenesis \[[@R10]\] and endocrine differentiation \[[@R28], [@R29]\] during pancreatic development.

To date there is insufficient available information regarding the expression of integrins on PaSCs in the developing human pancreas, although α5β1 integrin expression in rat adult PaSCs has been previously reported \[[@R11]\]. The present study examined the integrins associated with isolated human fetal PaSCs, and showed predominately high levels of α3β1 and α5β1. Examination of the relationship between ECM proteins and integrins required for human fetal PaSC adhesion and migration, demonstrated that collagen I plays a significant role through α3β1 integrin signaling. Culturing human fetal PaSCs on a collagen I matrix not only resulted in increased PaSC proliferation, but also significantly increased TGFβ1 and CTGF protein levels. Both TGFβ1 and CTGF are released by PaSCs and act upon PaSCs via autocrine signaling to control migration, proliferation, synthesis and secretion of ECM proteins \[[@R30]-[@R32]\]. Thus, increasing TGFβ1 and CTGF protein levels in cultured human PaSCs could promote a positive feedback loop to enhance cell adhesion, migration, and secretion in response to collagen I, specifically through α3β1 integrin. In contrast to human fetal PaSCs, α5β1 integrin is required for rat adult PaSC adhesion and migration on fibronectin under the CTGF stimulation \[[@R11]\], and blocking α5β1 integrin led to inhibited rat adult PaSC activation and function \[[@R33]\]. In hepatic stellate cells (HSCs), the interaction of β3 integrin with collagen I is required for HSC migration and survival, while inhibition of β3 integrin is sufficient for inducing HSC apoptosis and halting cell migration on collagen I matrix \[[@R34]\]. The differences in the integrin subunits and ECM interactions seen in the current PaSC study compared to others could be due to the cell types (HSCs *vs*. PaSCs), ages (fetal *vs*. adult), and species (human *vs*. rat). Our data demonstrated that the interaction between α3β1 integrin and the ECM protein collagen I is essential for the proliferation and function of human fetal PaSCs *in vitro*.

Importantly, the current findings were in agreement with previous reports showing that β1 integrin is predominately expressed in PaSCs \[[@R11]\]. Our previous study also showed that mice with β1 integrin deficiency under control of the collagen I promoter directly affected PaSC function and survival \[[@R10]\]. Using a neutralizing antibody to block β1 integrin activity on human fetal PaSCs, we found significantly inhibited cell adhesion, migration, proliferation, and growth factor production, along with reduced phosphorylation of the FAK/ERK and downstream cyclin D1 signaling that was independent of PI3K/AKT activation. In several model systems, β1 integrin has been shown to activate the FAK/ERK signaling cascade to enhance cell survival and function \[[@R35], [@R36]\]. Neutralizing antibodies against β1 and α3 integrin subunits could inhibit collagen I-induced activation of the FAK/ERK pathway in ovarian cancer cell lines \[[@R37]\]; however, enhanced activation of β1 integrin promotes phosphorylation of FAK, as seen in studies examining human lung fibroblasts viability \[[@R38]-[@R40]\]. Mantoni et al. \[[@R41]\] determined that PaSCs protect pancreatic cancer cells that had escaped from radiation through β1 integrin signaling via the FAK, but not the PI3K/AKT pathway. In addition, Lu et al. \[[@R42]\] found in their PaSC-induced cancer cell migration study that collagen I is the major factor to enhance α2β1 integrin expression, which lead to activation of the FAK signaling pathway. Our previous *in vitro* studies also demonstrated that collagen I promoted human fetal islet cell differentiation and proliferation through β1 integrin via downstream FAK/ERK phosphorylation \[[@R13]\], while only α3 integrin mediated signaling through the PI3K/AKT pathway \[[@R43]\]. Furthermore, β1 integrin signaling via the FAK/ERK pathway was verified in a mouse model with a collagen I-producing cell specific β1 integrin deficiency; these mice exhibited a severe loss of β-cell mass, suggesting that β1 integrin/FAK/ERK signaling is required for PaSC functions involved in β-cell differentiation and survival \[[@R10], [@R44]\]. Taken together, our present findings demonstrate that the β1 integrin/FAK/ERK signaling pathway is critical for human fetal PaSC function and survival.

In summary, the present study provides insight into the expression of integrin receptors in human fetal PaSCs and sheds light on how the β1 integrin, in association with its binding partner α3 subunit, interacts with the ECM protein collagen I and plays multiple roles in PaSC biology. β1 integrin interacts with the ECM to activate the FAK and ERK signaling pathway, which are important in maintaining proper PaSC function, along with increased cyclin D1 that leads to PaSC proliferation. These findings indicate that β1 integrin is required for the function and proliferation of human fetal PaSCs, and future applications of this research could contribute to the biomedical engineering of the ECM microenvironment needed for the efficient regulation of pancreatic development.

MATERIALS AND METHODS {#s4}
=====================

Human fetal PaSCs isolation and culture {#s4_1}
---------------------------------------

Human fetal pancreata (17-21 weeks fetal age) were collected according to protocols approved by the Health Sciences Research Ethics Board at the University of Western Ontario, in accordance with the Canadian Council on Health Sciences Research Involving Human Subjects guidelines. Pancreatic tissues were carefully dissected from surrounding tissues and immediately digested using dissociation buffer containing collagenase V (1 mg/ml; Sigma, St. Louis, MO, USA), followed by filtration through a 250 μm nylon mesh to yield fine cell-clusters \[[@R22]\]. PaSCs were isolated from dissociated human fetal pancreatic cell clusters using a modified outgrowth method as described previously \[[@R14]\]. In brief, cell clusters were seeded in uncoated culture T25 flasks (Fisher Scientific, Ottawa, ON, Canada) and cultured in Dulbecco\'s modified Eagle\'s medium (DMEM)/Ham\'s F12 (1:1 v/v) containing 10 % fetal bovine serum (FBS, Invitrogen, Burlington, ON, Canada). Eighteen hours after seeding, culture medium was changed with moving non-adhered cell clusters. The PaSCs grew out from the cell clusters over a 72 hours period. PaSC purity was assessed after the 2^nd^ passage by immunofluorescence staining and western blot analysis for stellate cell selective markers.

Adhesion and migration assay {#s4_2}
----------------------------

For the adhesion assay, 1×10^3^ PaSCs/well were plated on 96-well tissue culture plate pre-coated with 5μg/ml of either collagen I, collagen IV (BD Biosciences, Mississauga, ON, Canada), fibronectin, laminin (Chemicon, Temecula, CA, USA), or control (1% BSA, Sigma) in serum-free DEMEM/Ham\'s F12 (1:1 v/v) plus 1% BSA media for 20 minutes. Non-adhered cells were removed by washing the wells twice with sterile phosphate buffered saline (PBS). Six random fields per well were imaged at 40X magnification using an inverted light microscope (Leica DM IL; Leica Microsystems Inc., Concord, ON, Canada) and analyzed with Image ProPlus software (Media Cybernetics Inc., Rockville, MD, U.S.A). Adhered cells were counted manually, and data were expressed as fold change versus control.

To measure the migration rate of PaSCs, a wound-healing assay was adopted \[[@R45]\]. 1×10^4^ PaSCs/well were plated on 96-well tissue culture plate pre-coated with 5μg/ml of either collagen I, collagen IV, fibronectin, laminin, or control in serum-free media for 24 hours. After reaching confluence, the monolayers were wounded by scraping using a 10μl pipette tip and incubated with serum-free media for an additional 24 hours \[[@R45]\]. In each well, images of three different segments of the 'wound' area were captured 0 hour and 24 hours after damage. Each experiment was conducted in triplicate with at least four repeat experiments per group.

Blocking of β1 integrin using immunoneutralizing antibody {#s4_3}
---------------------------------------------------------

PaSCs were pre-incubated with either anti-human β1 integrin antibody (CD29, 5μg/ml), human IgG2a isotype-matched negative control (5μg/ml, BD Biosciences, San Diego, CA, USA), or fresh media (DMEM/Ham\'s F12 plus 1% BSA) for 1 hour prior to seeding on collagen I (5μg/ml) pre-coated tissue culture plates \[[@R9], [@R12], [@R13], [@R43]\]. Cells were then cultured with DEMEM/Ham\'s F12 plus 1% BSA media for 24 hours. At the end of the culture period, cells were subjected to adhesion and migration assays, or harvested for protein preparation or immunocytochemical studies. All culture experiments were conducted in triplicate with at least 3 repeat experiments per group.

Immunofluorescence staining {#s4_4}
---------------------------

For in-situ cell staining, PaSCs were cultured on coverslips (Fisher Scientific) pre-coated with poly-L-lysine (Sigma) for 1-3 days. Immunofluorescence staining was conducted using the antibodies as listed in Table [1](#T1){ref-type="table"}.

###### List of antibodies used for immunofluorescence and/or western blotting analysis

  Primary Antibody                                 Dilution                                              Company, Location
  ------------------------------------------------ ----------------------------------------------------- ----------------------------------------------------------
  Mouse anti-α-Smooth Muscle Actin                 1:50[^a^](#tfn-001){ref-type="table-fn"} or 1:1000    Dako, Mississauga, ON, Canada
  Mouse anti-Vimentin                              1:200[^a^](#tfn-001){ref-type="table-fn"} or 1:3000   Millipore, Temecula, CA, USA
  Mouse anti-GFAP                                  1:50[^a^](#tfn-001){ref-type="table-fn"} or 1:500     BD Pharmingen, Mississauga, ON, Canada
  Rabbit anti-Desmin                               1:100[^a^](#tfn-001){ref-type="table-fn"} or 1:1000   Abcam, Cambridge, MA, USA
  Mouse anti-collagen I                            1:50[^a^](#tfn-001){ref-type="table-fn"}              Santa Cruz, Montreal, QC, Canada
  Mouse anti-collagen IV                           1:100[^a^](#tfn-001){ref-type="table-fn"}             Chemicon, Temecula, CA, USA
  Rabbit anti-Laminin                              1:100[^a^](#tfn-001){ref-type="table-fn"}             Developmental Studies Hybridoma Bank, Iowa City, IA, USA
  Mouse anti-Fibronectin                           1:100[^a^](#tfn-001){ref-type="table-fn"}             Chemicon, Temecula, CA, USA
  Mouse anti-CK19                                  1:50[^a^](#tfn-001){ref-type="table-fn"}              Dako, Mississauga, ON, Canada
  Mouse anti-Stromal cell surface marker           1:50[^a^](#tfn-001){ref-type="table-fn"}              Developmental Studies Hybridoma Bank, Iowa City, IA, USA
  Mouse anti-β1                                    1:100[^a^](#tfn-001){ref-type="table-fn"} or 1:1000   Chemicon, Temecula, CA, USA
  Rabbit anti-β3                                   1:50[^a^](#tfn-001){ref-type="table-fn"}              Abcam, Cambridge, MA, USA
  Rabbit anti-α1                                   1:50[^a^](#tfn-001){ref-type="table-fn"}              Santa Cruz, Montreal, QC, Canada
  Rabbit anti-α2                                   1:100[^a^](#tfn-001){ref-type="table-fn"} or 1:2000   Santa Cruz, Montreal, QC, Canada
  Rabbit anti-α3                                   1:200[^a^](#tfn-001){ref-type="table-fn"}or 1:2000    Chemicon, Temecula, CA, USA
  Rabbit anti-α5                                   1:500[^a^](#tfn-001){ref-type="table-fn"}or 1:5000    Chemicon, Temecula, CA, USA
  Rabbit anti-αV                                   1:200[^a^](#tfn-001){ref-type="table-fn"}or 1:2000    Santa Cruz, Montreal, QC, Canada
  Mouse anti-Ki67                                  1:100[^a^](#tfn-001){ref-type="table-fn"}             BD Pharmingen, Mississauga, ON, Canada
  Mouse anti-phosphorylated Akt (Ser 473)          1:2000                                                Cell Signaling, Danvers, MA, USA
  Rabbit anti-Akt                                  1:2000                                                Cell Signaling, Danvers, MA, USA
  Rabbit anti-phosphorylated Thr202/Tyr204 ERK12   1:2000                                                Cell Signaling, Danvers, MA, USA
  Rabbit anti-ERK1/2                               1:1000                                                Cell Signaling, Danvers, MA, USA
  Rabbit anti-phosphorylated FAK (Try397)          1:2000                                                Abcam, Cambridge, MA, USA
  Rabbit anti-FAK                                  1:3000                                                Cell Signaling, Danvers, MA, USA
  Mouse anti-CyclinD1                              1:2000                                                Cell Signaling, Danvers, MA, USA
  Rabbit anti-TGF-β1                               1:1000                                                Sigma, St Louis, MO, USA
  Goat anti-CTGF                                   1:1000                                                Santa Cruz, Montreal, QC, Canada
  Mouse anti-Calnexin                              1:2000                                                BD Biosciences, Mississauga, ON, Canada
  Rabbit anti-GAPDH                                1:2000                                                Santa Cruz, Montreal, QC, Canada

dilution factor used for immunofluorescence.

For quantitative analysis of Ki67 labeling in PaSCs, experimental cell groups at the end of the culture were harvested and fixed in 4% PFA, embedded in 2% agarose gel and processed into tissue blocks \[[@R43]\]. Cell sections (4μm) were stained for Ki67 and nuclei were counterstained with DAPI. The percentage of Ki67^+^ cells was calculated by counting at least 500 cells per section per experimental group, with a minimum of 3 repeat experiments per group.

Protein extraction and western blotting {#s4_5}
---------------------------------------

Protein from PaSCs was extracted in a NP-40 lysis buffer. Equal amount of protein from each experimental group was fractionated by 7.5% or 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred onto a nitrocellulose membrane (Bio-Rad Laboratories, Mississauga, ON, Canada). Membranes were incubated with primary antibodies of appropriate dilution as listed in Table [1](#T1){ref-type="table"}, followed by the application of appropriate horse radish peroxidase (HRP)-conjugated secondary antibodies. Proteins were detected using ECL™-Plus Western blot detection reagents (Perkin Elmer, Wellesley, MA, USA) and imaged by the Versadoc Imaging System (Bio-Rad Laboratories). Bands were densitometrically quantified by Image Lab 3.0 software (Bio-Rad Laboratories) and normalized to appropriate loading controls \[[@R9], [@R13], [@R43]\].

Statistical analysis {#s4_6}
--------------------

Data are expressed as mean ± SEM. Statistical significance was determined using the paired Student\'s *t-*test when comparing two groups, or one-way ANOVA followed by Tukey\'s and/or Fisher\'s least significant difference post-hoc test when comparing more than two groups using GraphPad Prism software program (Version 5.0c, GraphPad Software Inc., La Jolla, CA, USA) or SPSS software (version 19.0, SPSS Inc, Chicago, IL, USA). Differences were considered to be statistically significant when *p* \< 0.05.
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